- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Teva Cites Biosimilar Strength in Third-Quarter Earnings
Launched in the US market in late 2019, Truxima (rituximab) has become a significant revenue driver for Teva.
Israel-based Teva Pharmaceutical Industries reported revenues of $4 billion for the third quarter of 2020 and said earnings were driven in part by rituximab biosimilar (Truxima), which it launched on the US market in 2019 in partnership with Celltrion Healthcare.
Celltrion developed the product, which became the first rituximab biosimilar approved by the FDA in November 2018.
The company reported combined biosimilar and generic product revenues of $928 million for the third quarter, which is up 2% vs the year-ago quarter. “This increase was mainly due to higher revenues from Truxima and from our ProAir (albuterol inhaler) authorized generic, partially offset by lower volume of other generic products,” a Teva statement said. Specific product revenues for Truxima, Teva’s first biosimilar offering, were not provided.
Also in conjunction with Celltrion, Teva launched the trastuzumab biosimilar Herzuma in the United States in March 2020. In August, the company announced a partnership with Alvotech to commercialize 5 unnamed biosimilars in the United States.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
